Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Abstract

EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) investigators - Portugal: Mafalda Bourbon (NLI), Ana C. Alves, Ana M. Medeiros (Unidade I&D, Grupo de Investigação Cardiovascular, Dept. de Promoção da Saúde e Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa; University of Lisboa, Faculty of Sciences, BioISI – Biosystems & Integrative Sciences Institute, Lisboa).Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries.Highlights: The EAS FHSC is an international initiative involving a network of investigators interested in FH from around 70 countries; Information on FH prevalence is lacking in most countries; where available, data tend to align with contemporary estimates; FH diagnosis and management varies widely across countries, with overall suboptimal identification and under-treatment; In most countries diagnosis primarily relies on DLCN criteria, and less frequently on Simon Broom or MEDPED; Therapy for FH is not universally reimbursed, and criteria vary across countries. Access to PCSK9i and apheresis is limited.info:eu-repo/semantics/publishedVersio